x
Filter:
Filters applied
- Molecular Bases of Disease
- NF-κB transcription factorRemove NF-κB transcription factor filter
Keyword
- astrocyte1
- autophagy1
- carbon dioxide1
- chronic obstructive pulmonary disease (COPD)1
- CO21
- diabetes1
- epidermal growth factor (EGF)1
- glutamate1
- hypercapnia1
- immunity1
- inflammation1
- innate immunity1
- intestine1
- iron metabolism1
- lipid droplet1
- manganese1
- nuclear factor 2 (erythroid-derived 2-like factor, NFE2L2, Nrf2)1
- obesity1
- p1001
- p38 MAPK1
- RelB1
- ribosomal inactivation1
- signal transduction1
Molecular Bases of Disease
4 Results
- Cell BiologyOpen Access
Carbon dioxide-dependent regulation of NF-κB family members RelB and p100 gives molecular insight into CO2-dependent immune regulation
Journal of Biological ChemistryVol. 292Issue 27p11561–11571Published online: May 15, 2017- Ciara E. Keogh
- Carsten C. Scholz
- Javier Rodriguez
- Andrew C. Selfridge
- Alexander von Kriegsheim
- Eoin P. Cummins
Cited in Scopus: 19CO2 is a physiological gas normally produced in the body during aerobic respiration. Hypercapnia (elevated blood pCO2 >≈50 mm Hg) is a feature of several lung pathologies, e.g. chronic obstructive pulmonary disease. Hypercapnia is associated with increased susceptibility to bacterial infections and suppression of inflammatory signaling. The NF-κB pathway has been implicated in these effects; however, the molecular mechanisms underpinning cellular sensitivity of the NF-κB pathway to CO2 are not fully elucidated. - Molecular Bases of DiseaseOpen Access
Non-mutagenic Suppression of Enterocyte Ferroportin 1 by Chemical Ribosomal Inactivation via p38 Mitogen-activated Protein Kinase (MAPK)-mediated Regulation: EVIDENCE FOR ENVIRONMENTAL HEMOCHROMATOSIS
Journal of Biological ChemistryVol. 291Issue 38p19858–19872Published online: July 21, 2016- Chang-Kyu Oh
- Seong-Hwan Park
- Juil Kim
- Yuseok Moon
Cited in Scopus: 4Iron transfer across the basolateral membrane of an enterocyte into the circulation is the rate-limiting step in iron absorption and is regulated by various pathophysiological factors. Ferroportin (FPN), the only known mammalian iron exporter, transports iron from the basolateral surface of enterocytes, macrophages, and hepatocytes into the blood. Patients with genetic mutations in FPN or repeated blood transfusion develop hemochromatosis. In this study, non-mutagenic ribosomal inactivation was assessed as an etiological factor of FPN-associated hemochromatosis in enterocytes. - Cell BiologyOpen Access
Advanced Glycation End Products (AGE) Potently Induce Autophagy through Activation of RAF Protein Kinase and Nuclear Factor κB (NF-κB)
Journal of Biological ChemistryVol. 291Issue 3p1481–1491Published online: November 19, 2015- Neeharika Verma
- Sunil K. Manna
Cited in Scopus: 34Advanced glycation end products (AGE) accumulate in diabetic patients and aging people because of high amounts of three- or four-carbon sugars derived from glucose, thereby causing multiple consequences, including inflammation, apoptosis, obesity, and age-related disorders. It is important to understand the mechanism of AGE-mediated signaling leading to the activation of autophagy (self-eating) that might result in obesity. We detected AGE as one of the potent inducers of autophagy compared with doxorubicin and TNF. - Molecular Bases of DiseaseOpen Access
Transcriptional Regulation of the Astrocytic Excitatory Amino Acid Transporter 1 (EAAT1) via NF-κB and Yin Yang 1 (YY1)
Journal of Biological ChemistryVol. 290Issue 39p23725–23737Published online: August 12, 2015- Pratap Karki
- Clifford Kim
- Keisha Smith
- Deok-Soo Son
- Michael Aschner
- Eunsook Lee
Cited in Scopus: 48Background: The mechanism for transcriptional regulation of EAAT1 remains to be elucidated.Results: EGF-activated NF-κB is a positive regulator of EAAT1, whereas manganese-activated YY1, with HDACs acting as co-repressors, is a negative regulator.Conclusion: NF-κB and YY1 are two critical transcriptional regulators of EAAT1.Significance: Identifying the molecular targets of EAAT1 regulation is crucial to develop therapeutics against neurological disorders associated with impairment of EAAT1.